12:33 PM
May 17, 2019
 |  BC Extra  |  Company News

May 17 Company Quick Takes: A trio of FDA approvals; plus Ligand/Cumulus, Revlimid

Takeda's Gattex gets pediatric approval
FDA approved Gattex teduglutide from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502; NYSE:TAK) to include treatment of patients age one and older with short bowel syndrome who are dependent on parenteral support, expanding the drug's initial adult indication. Takeda's Shire plc unit gained the analog of GLP-2 through its 2015 acquisition of NPS Pharmaceuticals Inc. in a $5.2 billion deal.

FDA approves first anticoagulant for pediatric patients
FDA also approved...

Read the full 333 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >